Overview

Location [1]
9p21.3
Pathway
Cell cycle control
Protein [2]
Cyclin-dependent kinase 4 inhibitor B
Synonyms [1]
P15, TP15, MTS2, p15INK4b, CDK4I, INK4B

Cyclin-dependent kinase inhibitor 2B (CDKN2B, also known as p15) is a gene that encodes a protein that binds to CDK4 or CDK6 and inhibits their activation. Missense and silent mutations are observed in cancers such as intestinal cancer, kidney cancer, and cancers of the urinary tract.

CDKN2B is altered in 7.57% of all cancers with malignant glioma, non-small cell lung carcinoma, melanoma, bladder carcinoma, and pancreatic exocrine neoplasm having the greatest prevalence of alterations [3].

CDKN2B GENIE Cases - Top Diseases

The most common alterations in CDKN2B are CDKN2B Loss (7.27%), CDKN2B Mutation (0.27%), CDKN2B Amplification (0.07%), CDKN2B A70V (0.01%), and CDKN2B E121K (0.01%) [3].

CDKN2B GENIE Cases - Top Alterations

Significance of CDKN2B in Diseases

Glioblastoma +

Glioma +

Meningioma +

Malignant Glioma +

Malignant Solid Tumor +

Primary Central Nervous System Lymphoma +

Astrocytoma +

Cholangiocarcinoma +

Ependymoma +

Oligodendroglioma +

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20170629. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.